The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology
- 14 November 2016
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 11 (1) , 33-41
Abstract
Ulcerative colitis (uc) is a chronic condition and for the vast majority of patients, life-long treatment is required. low adherence to therapy is an emerging issue. since low adherence is associated with poor clinical outcomes and increased costs, it is becoming crucial to identify strategies in order to improve it. Areas covered: We performed literature searches in PubMed using the terms 'adherence', 'mesalamine', 'budesonide MMX', 'MMX technology' in combination with 'ulcerative colitis'. Firstly, we present the key-concepts of therapy for UC and discuss the problem of the adherence and how to measure it. Then, we provide data on the extent of the problem and the causes and consequences from clinical and economic point of views. Finally, we focus on treatment-related variables associated with non-adherence and treatment-related strategies to improve adherence, paying particular attention to Multi Matrix system (MMX) technology applied to mesalazine and budesonide. Expert commentary: The pharmaceutical industry and scientific community are making efforts to simplify treatments for UC. MMX technology, which allows a reduction in the number of pills to be taken and daily administrations, may facilitate adherence to treatment and carry further clinical benefits.Keywords
This publication has 71 references indexed in Scilit:
- Overview of Biological Therapy in Ulcerative Colitis: Current and Future DirectionsJournal of Gastrointestinal and Liver Diseases, 2015
- Self-reported Disability in Patients with Inflammatory Bowel Disease Largely Determined by Disease Activity and Illness PerceptionsInflammatory Bowel Diseases, 2015
- European evidence based consensus on surgery for ulcerative colitisJournal of Crohn's and Colitis, 2014
- 5-Aminosalicylates Reduce the Risk of Colorectal Neoplasia in Patients with Ulcerative Colitis: An Updated Meta-AnalysisPLOS ONE, 2014
- Use of Thiopurines and Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Diseases: A Meta-AnalysisPLOS ONE, 2013
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2013
- Ulcerative ColitisNew England Journal of Medicine, 2011
- Epidemiology and Natural History of Inflammatory Bowel DiseasesGastroenterology, 2011
- Review: Current trends in inflammatory bowel disease: the natural historyTherapeutic Advances in Gastroenterology, 2010
- Change in The Extent of Colonoscopic and Histological Involvement in Ulcerative Colitis Over TimeAmerican Journal of Gastroenterology, 1999